2023 Q4 Form 8-K Financial Statement

#000114036124016719 Filed on April 01, 2024

View on sec.gov

Income Statement

Concept 2023 Q4 2023 2022
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue $164.9K $164.9K
YoY Change
Gross Profit $3.966M $3.966M
YoY Change
Gross Profit Margin
Selling, General & Admin $113.8K $20.75M
YoY Change
% of Gross Profit 2.87% 523.24%
Research & Development $9.716M $9.716M
YoY Change
% of Gross Profit 244.96% 244.96%
Depreciation & Amortization $60.40K $60.40K
YoY Change
% of Gross Profit 1.52% 1.52%
Operating Expenses $4.505M $33.28M $18.50M
YoY Change -36.38% 79.88% 1229.36%
Operating Profit -$539.1K -$33.28M -$18.50M
YoY Change 79.88% 1229.36%
Interest Expense $3.448M $13.85M $4.257M
YoY Change 37.63% 225.38% 59864.37%
% of Operating Profit
Other Income/Expense, Net $34.59K $14.93M $4.257M
YoY Change 250.77%
Pretax Income -$1.023M -$18.34M -$14.24M
YoY Change -77.64% 28.79% 928.66%
Income Tax $861.1K $3.549M $979.5K
% Of Pretax Income
Net Earnings -$9.178M -$21.89M -$15.22M
YoY Change 76.55% 43.82% 999.41%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$0.05 -$0.59 -$0.41
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2023 Q4 2023 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $395.0K $395.0K $990.00
YoY Change 39800.0% 39800.0% -99.7%
Cash & Equivalents $395.0K $395.0K $990.00
Short-Term Investments
Other Short-Term Assets $0.00 $0.00 $168.4K
YoY Change -100.0% -100.0% -30.14%
Inventory
Prepaid Expenses $0.00
Receivables $81.00K $81.00K
Other Receivables $0.00
Total Short-Term Assets $395.0K $395.0K $169.3K
YoY Change 133.27% 133.26% -70.22%
LONG-TERM ASSETS
Property, Plant & Equipment $29.20K $382.4K
YoY Change
Goodwill $0.00
YoY Change
Intangibles $0.00
YoY Change
Long-Term Investments $310.6M $310.6M $300.3M
YoY Change 3.43% 3.43% 2.41%
Other Assets $0.00
YoY Change -100.0%
Total Long-Term Assets $310.6M $310.6M $300.3M
YoY Change 3.43% 3.43% 2.35%
TOTAL ASSETS
Total Short-Term Assets $395.0K $395.0K $169.3K
Total Long-Term Assets $310.6M $310.6M $300.3M
Total Assets $311.0M $311.0M $300.5M
YoY Change 3.5% 3.5% 2.21%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.601M $1.601M
YoY Change
Accrued Expenses $47.10M $47.56M $17.57M
YoY Change 174.39% 170.75% 3532.97%
Deferred Revenue $4.413M
YoY Change
Short-Term Debt $6.783M $6.783M $3.501M
YoY Change 93.75% 93.75%
Long-Term Debt Due $0.00 $41.82M
YoY Change
Total Short-Term Liabilities $56.18M $56.18M $22.47M
YoY Change 149.98% 149.98% 3187.72%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $10.06M $10.06M $10.06M
YoY Change 0.0% 0.0% 0.0%
Total Long-Term Liabilities $10.06M $10.06M $10.06M
YoY Change 0.0% 0.0% 0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $56.18M $56.18M $22.47M
Total Long-Term Liabilities $10.06M $10.06M $10.06M
Total Liabilities $66.24M $66.24M $32.54M
YoY Change 103.59% 103.59% 202.77%
SHAREHOLDERS EQUITY
Retained Earnings -$63.87M
YoY Change 106.11%
Common Stock $8.800K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost) $0.00
YoY Change
Treasury Stock Shares
Shareholders Equity -$63.87M $244.8M $268.0M
YoY Change
Total Liabilities & Shareholders Equity $311.0M $311.0M $300.5M
YoY Change 3.5% 3.5% 2.21%

Cashflow Statement

Concept 2023 Q4 2023 2022
OPERATING ACTIVITIES
Net Income -$9.178M -$21.89M -$15.22M
YoY Change 76.55% 43.82% 999.41%
Depreciation, Depletion And Amortization $60.40K $60.40K
YoY Change
Cash From Operating Activities -$3.433M -$5.136M -$1.378M
YoY Change 630.56% 272.61% 23.71%
INVESTING ACTIVITIES
Capital Expenditures $2.200K $2.200K
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $3.540M -$2.816M
YoY Change -100.0% -225.69% -99.04%
Cash From Investing Activities $0.00 $3.540M -$2.816M
YoY Change -100.0% -225.69% -99.04%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 542.0K 1.990M 3.868M
YoY Change 31.9% -48.55% -98.69%
NET CHANGE
Cash From Operating Activities -3.433M -5.136M -1.378M
Cash From Investing Activities 0.000 3.540M -2.816M
Cash From Financing Activities 542.0K 1.990M 3.868M
Net Change In Cash -2.891M 394.0K -326.7K
YoY Change 14452800.0% -220.59% -199.7%
FREE CASH FLOW
Cash From Operating Activities -$3.433M -$5.136M -$1.378M
Capital Expenditures $2.200K $2.200K
Free Cash Flow -$3.435M -$5.138M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
8716023
CY2023 us-gaap Legal Fees
LegalFees
20752819
CY2022 us-gaap Legal Fees
LegalFees
10004519
CY2023 djt Franchise Tax Expense
FranchiseTaxExpense
282500
CY2022 djt Franchise Tax Expense
FranchiseTaxExpense
200000
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-33276051
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-18920542
CY2023 us-gaap Insurance Recoveries
InsuranceRecoveries
1081238
CY2022 us-gaap Insurance Recoveries
InsuranceRecoveries
0
CY2023 us-gaap Investment Income Interest
InvestmentIncomeInterest
13852774
CY2022 us-gaap Investment Income Interest
InvestmentIncomeInterest
4257469
CY2023 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
14934012
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4257469
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-18342039
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-14663073
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
979475
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-21890641
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-15642548
CY2023 us-gaap Profit Loss
ProfitLoss
-21890641
CY2022 djt Interest Earned On Cash And Marketable Securities Held In Trust Account
InterestEarnedOnCashAndMarketableSecuritiesHeldInTrustAccount
4257469
CY2023 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
29549831
CY2022 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
17026986
CY2023 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
810606
CY2022 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
979475
CY2023 us-gaap Increase Decrease In Prepaid Insurance
IncreaseDecreaseInPrepaidInsurance
-168350
CY2022 us-gaap Increase Decrease In Prepaid Insurance
IncreaseDecreaseInPrepaidInsurance
-237673
CY2023 djt Increase Decrease Franchise Tax Payable
IncreaseDecreaseFranchiseTaxPayable
58226
CY2022 djt Increase Decrease Franchise Tax Payable
IncreaseDecreaseFranchiseTaxPayable
200000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1455883
CY2023 djt Payments For Investment Of Cash In Trust Account
PaymentsForInvestmentOfCashInTrustAccount
0
CY2022 djt Payments For Investment Of Cash In Trust Account
PaymentsForInvestmentOfCashInTrustAccount
2875000
CY2023 djt Proceeds From Trust Account For Taxes
ProceedsFromTrustAccountForTaxes
3232500
CY2023 djt Investments Withdrawn From Trust Account For Redemptions
InvestmentsWithdrawnFromTrustAccountForRedemptions
307028
CY2022 djt Investments Withdrawn From Trust Account For Redemptions
InvestmentsWithdrawnFromTrustAccountForRedemptions
58916
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
3539528
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2816084
CY2023 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
1008945
CY2022 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
2875000
CY2023 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
1773000
CY2022 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
503441
CY2023 us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
-484835
CY2022 us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
625700
CY2023 djt Repayment Of Shares
RepaymentOfShares
307028
CY2022 djt Repayment Of Shares
RepaymentOfShares
58916
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1990082
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3945225
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
394022
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-326742
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
989
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
327731
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
395011
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
989
CY2023 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
2737997
CY2022 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
CY2023 us-gaap Interest Paid Net
InterestPaidNet
0
CY2022 us-gaap Interest Paid Net
InterestPaidNet
0
CY2023 djt Temporary Equity Accretion To Redemption Value Non Cash Transaction
TemporaryEquityAccretionToRedemptionValueNonCashTransaction
10000857
CY2022 djt Temporary Equity Accretion To Redemption Value Non Cash Transaction
TemporaryEquityAccretionToRedemptionValueNonCashTransaction
5760092
CY2023 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
500000
CY2022 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
0
CY2023 djt Condition For Future Business Combination Number Of Businesses Minimum
ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum
1
CY2023 djt Percentage Obligation To Redeem Public Shares If Entity Does Not Complete Business Combination
PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination
1
CY2023Q4 djt Minimum Net Tangible Assets Upon Consummation Of Business Combination
MinimumNetTangibleAssetsUponConsummationOfBusinessCombination
5000001
CY2023 djt Redemption Limit Percentage Without Prior Consent
RedemptionLimitPercentageWithoutPriorConsent
0.15
CY2023Q4 djt Minimum Net Tangible Assets Upon Redemption Of Temporary Equity
MinimumNetTangibleAssetsUponRedemptionOfTemporaryEquity
5000001
CY2023 djt Percentage Obligation To Redeem Public Shares If Entity Does Not Complete Business Combination
PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination
1
CY2023 djt Percentage Obligation To Redeem Public Shares If Entity Does Not Complete Business Combination
PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination
1
CY2023 djt Maximum Allowed Dissolution Expenses
MaximumAllowedDissolutionExpenses
100000
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2023Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2023 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
109217
CY2022 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0
CY2023Q4 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2022Q3 djt Percentage Of Excise Tax Of Fair Market Value Of Shares Repurchased
PercentageOfExciseTaxOfFairMarketValueOfSharesRepurchased
0.01
CY2021Q3 djt Number Of Warrants Issued Per Unit
NumberOfWarrantsIssuedPerUnit
1
CY2023 djt Restrictions On Transfer Period Of Time After Business Combination Completion
RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion
P30D
CY2023 us-gaap Litigation Settlement Amount Awarded To Other Party
LitigationSettlementAmountAwardedToOtherParty
500000
CY2023Q4 djt Maximum Number Of Demands For Registration Of Securities
MaximumNumberOfDemandsForRegistrationOfSecurities
3
CY2023Q4 djt Percentage Of Cash Underwriting Discount Based On Gross Proceeds From Ipo
PercentageOfCashUnderwritingDiscountBasedOnGrossProceedsFromIpo
-0.0125
CY2023Q4 djt Aggregate Cash Underwriting Discount If Over Allotment Exercised In Full
AggregateCashUnderwritingDiscountIfOverAllotmentExercisedInFull
3593750
CY2023 djt Period Of Right Of First Refusal Allowed To Underwriter From Business Combination
PeriodOfRightOfFirstRefusalAllowedToUnderwriterFromBusinessCombination
P24M
CY2023 djt Litigation Settlement Expense Greater Than Actual Fees
LitigationSettlementExpenseGreaterThanActualFees
8000000
CY2023 djt Percentage Of Litigation Settlement Expense Greater Than Actual Fees
PercentageOfLitigationSettlementExpenseGreaterThanActualFees
1.30
CY2023 us-gaap Litigation Settlement Expense
LitigationSettlementExpense
5100000
CY2022 us-gaap Litigation Settlement Expense
LitigationSettlementExpense
0
CY2023Q3 us-gaap Litigation Settlement Expense
LitigationSettlementExpense
18000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023 djt Class Of Warrant Or Right Adjustment Of Redemption Price Of Warrants Or Rights Percent Based On Market Value And Newly Issued Price1
ClassOfWarrantOrRightAdjustmentOfRedemptionPriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrice1
1.15
CY2023 djt Trading Day Period To Calculate Volume Weighted Average Trading Price Following Notice Of Redemption
TradingDayPeriodToCalculateVolumeWeightedAverageTradingPriceFollowingNoticeOfRedemption
P30D
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
0
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
0
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Legal Settlements
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements
0
CY2023Q4 djt Deferred Tax Assets Start Up Costs
DeferredTaxAssetsStartUpCosts
8716458
CY2022Q4 djt Deferred Tax Assets Start Up Costs
DeferredTaxAssetsStartUpCosts
5190046
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
13278558
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
5190046
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
13278558
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
5190046
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2023 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
-3742611
CY2023 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0
CY2022 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0
CY2023 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
-796963
CY2022 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
-637053
CY2023 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0
CY2022 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0
CY2023 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-8088176
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-4695494
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3548602
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
979475
CY2023 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-8088176
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-4695494
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0435
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0435
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.441
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.3203
CY2023 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.006
CY2022 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0
CY2023 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.1935
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.0668
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001849635
CY2022Q4 us-gaap Other Liability Current Related Party Type Extensible Enumeration
OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration
http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2023Q4 us-gaap Other Liability Current Related Party Type Extensible Enumeration
OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration
http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2023 djt Redemption Period Upon Closure
RedemptionPeriodUponClosure
P5D
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2024Q1 dei Document Type
DocumentType
8-K
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-25
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
Trump Media & Technology Group Corp.
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q1 dei Entity File Number
EntityFileNumber
001-40779
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-4293042
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
401 N. Cattlemen Rd.
CY2024Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Ste. 200
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Sarasota
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
34232
CY2024Q1 dei City Area Code
CityAreaCode
941
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
735-7346
CY2024Q1 dei Written Communications
WrittenCommunications
false
CY2024Q1 dei Soliciting Material
SolicitingMaterial
false
CY2024Q1 dei Pre Commencement Tender Offer
PreCommencementTenderOffer
false
CY2024Q1 dei Pre Commencement Issuer Tender Offer
PreCommencementIssuerTenderOffer
false
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2024Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
395011
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
989
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
0
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
168350
CY2023Q4 us-gaap Assets Current
AssetsCurrent
395011
CY2022Q4 us-gaap Assets Current
AssetsCurrent
169339
CY2023Q4 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
310623083
CY2022Q4 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
300330651
CY2023Q4 us-gaap Assets
Assets
311018094
CY2022Q4 us-gaap Assets
Assets
300499990
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
47104743
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
18054912
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
3883945
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
2875000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
500000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
0
CY2023Q4 us-gaap Accrued Income Taxes
AccruedIncomeTaxes
1790081
CY2022Q4 us-gaap Accrued Income Taxes
AccruedIncomeTaxes
979475
CY2023Q4 djt Franchise Tax Payable
FranchiseTaxPayable
458226
CY2022Q4 djt Franchise Tax Payable
FranchiseTaxPayable
400000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2398700
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
625700
CY2023Q4 djt Advances Due To Related Parties Current
AdvancesDueToRelatedPartiesCurrent
41000
CY2022Q4 djt Advances Due To Related Parties Current
AdvancesDueToRelatedPartiesCurrent
525835
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
56176695
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
23460922
CY2023Q4 djt Deferred Offering Costs Noncurrent
DeferredOfferingCostsNoncurrent
10062500
CY2022Q4 djt Deferred Offering Costs Noncurrent
DeferredOfferingCostsNoncurrent
10062500
CY2023Q4 us-gaap Liabilities
Liabilities
66239195
CY2022Q4 us-gaap Liabilities
Liabilities
33523422
CY2023Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
308645005
CY2022Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
298951176
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
0
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
0
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-63866949
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-31975454
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-63866106
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-31974608
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
311018094
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
300499990
CY2023 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
12240732
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3548602
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-31974608
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-21890641
CY2023 us-gaap Stock Issued During Period Value Share Based Compensation Forfeited
StockIssuedDuringPeriodValueShareBasedCompensationForfeited
0
CY2023 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
10000857
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-63866106
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-10571968
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-15642548
CY2022 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
5760092
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-31974608
CY2022 us-gaap Profit Loss
ProfitLoss
-15642548
CY2023 djt Interest Earned On Cash And Marketable Securities Held In Trust Account
InterestEarnedOnCashAndMarketableSecuritiesHeldInTrustAccount
13831960
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5135588
CY2023 djt Redemption Of Common Stock Non Cash Transaction
RedemptionOfCommonStockNonCashTransaction
3
CY2022 djt Redemption Of Common Stock Non Cash Transaction
RedemptionOfCommonStockNonCashTransaction
0
CY2023 us-gaap Nature Of Operations
NatureOfOperations
<div style="color: rgb(35, 31, 32); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">NOTE 1. DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS AND GOING CONCERN </div> <div style="color: rgb(35, 31, 32); font-family: 'Times New Roman'; font-size: 10pt;"> <br/> </div> <div style="color: rgb(35, 31, 32); font-family: 'Times New Roman'; font-size: 10pt;">Digital World Acquisition Corp. (the “Company”) is a blank check company incorporated in the State of Delaware on December 11, 2020. The Company was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or other similar business combination with one or more businesses or entities (“Business Combination”). Although the Company is not limited to a particular industry or geographic region for purposes of consummating a Business Combination, the Company intends to focus on middle-market emerging growth technology-focused companies in the Americas, in the SaaS and Technology or Fintech and Financial Services sector. </div> <div style="color: rgb(35, 31, 32); font-family: 'Times New Roman'; font-size: 10pt;"> <br/> </div> <div style="color: rgb(35, 31, 32); font-family: 'Times New Roman'; font-size: 10pt;">As of December 31, 2023, the Company had not yet commenced operations. All activity through December 31, 2023 relates to the Company’s formation, the initial public offering (“Initial Public Offering”), which is described below and the search for targets for its initial Business Combination. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company generates non-operating income in the form of interest income on cash and cash equivalents from the proceeds derived from the Initial Public Offering and the concurrent Private Placement (as defined below). The Company has selected December 31 as its fiscal year end. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies.</div> <div style="color: rgb(35, 31, 32); font-family: 'Times New Roman'; font-size: 10pt;"> <br/> </div> <div style="color: rgb(35, 31, 32); font-family: 'Times New Roman'; font-size: 10pt;">The registration statement for the Company’s Initial Public Offering was declared effective on September 2,  2021 (the “Registration Statement”). On September 8, 2021, the Company consummated the Initial Public Offering of 28,750,000 units (the “Units” and, with respect to the shares of Class A common stock included in the Units sold, the “Public Shares”), at $10.00 per Unit, generating gross proceeds of $287,500,000, and incurred offering costs of $23,566,497, consisting of deferred underwriting commissions of $10,062,500 (see Note 4), fair value of the representative shares (as defined in Note 8) of $1,437,500, fair value of shares issued to the anchor investors of the Company’s Initial Public Offering of $7,677,450, fair value of shares transferred to officers and directors of $221,018, and other offering costs of $4,168,029. The Units sold in the Initial Public Offering included Units that were subject to a 45-day option granted to the underwriter to purchase up to an additional 3,750,000 Units at the Initial Public Offering price to cover over-allotment, which was exercised in full in connection with the consummation of the Initial Public Offering.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"> </div> <div style="color: rgb(35, 31, 32); font-family: 'Times New Roman'; font-size: 10pt;">Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of 1,133,484 units (the “Placement Units”) at a price of $10.00 per Placement Unit in a private placement (“Private Placement”) to the Company’s sponsor, ARC Global Investments II LLC (the “Sponsor”), generating gross proceeds of $11,334,840, which is described in Note 5.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"> </div> <div style="color: rgb(35, 31, 32); font-family: 'Times New Roman'; font-size: 10pt;">Following the closing of the Initial Public Offering on September 8, 2021, an amount of $293,250,000 ($10.20 per Unit) from the net proceeds of the sale of the Units in the Initial Public Offering and the sale of the Placement Units was placed in a trust account (the “Trust Account”) located in the United States and invested only in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act of 1940, as amended (the “Investment Company Act”), with a maturity of 185 days or less or in money market funds meeting the conditions of paragraph (d) of Rule 2a-7 of the Investment Company Act, as determined by the Company, until the earliest of: (i) the completion of a Business Combination, (ii) the redemption of any Public Shares properly submitted in connection with a stockholder vote to amend the Company’s Amended and Restated Certificate of Incorporation (“Amended and Restated Certificate of Incorporation”) (A) to modify the substance or timing of the Company’s obligation to allow redemption in connection with its initial Business Combination or certain amendments to its Amended and Restated Certificate of Incorporation prior thereto or to redeem 100% of the Public Shares if the Company does not complete its initial Business Combination within the Combination Period (as defined below) or (B) with respect to any other provision relating to stockholders’ rights or pre-Business Combination activity and (iii) the redemption of 100% of the Public Shares if the Company is unable to complete an initial Business Combination within the Combination Period (subject to the requirements of applicable law).</div> <div style="color: rgb(35, 31, 32); font-family: 'Times New Roman'; font-size: 10pt;"> <br/> </div> <div style="color: rgb(35, 31, 32); font-family: 'Times New Roman'; font-size: 10pt;">The Company will provide its stockholders with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a stockholder meeting called to approve the Business Combination or (ii) by means of a tender offer. In connection with a proposed Business Combination, the Company may seek stockholder approval of a Business Combination at a meeting called for such purpose at which stockholders may seek to redeem their shares, regardless of whether they vote for or against a Business Combination. The Company will proceed with a Business Combination only if the Company has net tangible assets of at least $5,000,001 upon such consummation of a Business Combination and, if the Company seeks stockholder approval, a majority of the outstanding shares voted are voted in favor of the Business Combination, unless otherwise required by applicable law, regulation or stock exchange rules.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="color: rgb(35, 31, 32); font-family: 'Times New Roman'; font-size: 10pt;">If the Company seeks stockholder approval of a Business Combination and it does not conduct redemptions pursuant to the tender offer rules, the Company’s Amended and Restated Certificate of Incorporation provides that a public stockholder, together with any affiliate of such stockholder or any other person with whom such stockholder is acting in concert or as a “group” (as defined under Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), will be restricted from seeking redemption rights with respect to 15% or more of the Public Shares without the Company’s prior written consent.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"> </div> <div style="color: rgb(35, 31, 32); font-family: 'Times New Roman'; font-size: 10pt;">The stockholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account (initially $10.20 per share, plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations). The per-share amount to be distributed to stockholders who redeem their Public Shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriter. There will be no redemption rights upon the completion of a Business Combination with respect to the Company’s warrants.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="color: rgb(35, 31, 32); font-family: 'Times New Roman'; font-size: 10pt;">All of the Public Shares contain a redemption feature which allows for the redemption of such Public Shares in connection with the Company’s liquidation, if there is a stockholder vote or tender offer in connection with the Company’s Business Combination and in connection with certain amendments to the Company’s Amended and Restated Certificate of Incorporation. In accordance with the rules of the U.S. Securities and Exchange Commission (the “SEC”) and its guidance on redeemable equity instruments, which has been codified in ASC 480-10-S99, redemption provisions not solely within the control of a company require common stock subject to redemption to be classified outside of permanent equity. Because of the redemption feature noted above, the shares of Class A common stock are subject to ASC 480-10-S99. If it is probable that the equity instrument will become redeemable, the Company has the option to either (i) accrete changes in the redemption value over the period from the date of issuance (or from the date that it becomes probable that the instrument will become redeemable, if later) to the earliest redemption date of the instrument or (ii) recognize changes in the redemption value immediately as they occur and adjust the carrying amount of the instrument to equal the redemption value at the end of each reporting period. The Company has elected to recognize the changes immediately. The accretion or remeasurement is treated as a deemed dividend (i.e., a reduction to retained earnings, or in absence of retained earnings, additional paid-in capital). While redemptions cannot cause the Company’s net tangible assets to fall below $5,000,001, the Public Shares are redeemable and will be classified as such on the balance sheet until such date that a redemption event takes place.</div> <div style="color: rgb(35, 31, 32); font-family: 'Times New Roman'; font-size: 10pt;"> <br/> </div> <div style="color: rgb(35, 31, 32); font-family: 'Times New Roman'; font-size: 10pt;">If a stockholder vote is not required and the Company does not decide to hold a stockholder vote for business or other legal reasons, the Company will, pursuant to its Amended and Restated Certificate of Incorporation, offer such redemption pursuant to the tender offer rules of the SEC, and file tender offer documents containing substantially the same information as would be included in a proxy statement with the SEC prior to completing a Business Combination.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="color: rgb(35, 31, 32); font-family: 'Times New Roman'; font-size: 10pt;">The Sponsor and the Company’s officers and directors have agreed (a) to vote any shares of Class B common stock of the Company (the “Founder Shares”), the shares of Class A common stock included within the Placement Units (the “Private Shares”) and any Public Shares purchased during or after the Initial Public Offering in favor of a Business Combination, (b) waive their redemption rights with respect to any Founder Shares, Private Shares held by them and any Public Shares purchased during or after the Initial Public Offering in connection with the completion of the Business Combination, (c) not to waive their redemption rights with respect to any Founder Shares, Private Shares held by them and any Public Shares purchased during or after the Initial Public Offering in connection with a stockholder vote to approve an amendment to the Amended and Restated Certificate of Incorporation (A) to modify the substance or timing of the Company’s obligation to allow redemption in connection with its initial Business Combination or certain amendments to its Amended and Restated Certificate of Incorporation prior thereto or to redeem 100% of the Public Shares if the Company does not complete an initial Business Combination within the Combination Period or (B) with respect to any other provision relating to stockholders’ rights or pre-initial Business Combination activity and (iii) waive their rights to liquidating distributions from the Trust Account with respect to any Founder Shares and Private Shares held by them if the Company fails to complete its initial Business Combination within the Combination Period, although they will be entitled to liquidating distributions from the Trust Account with respect to any Public Shares they hold if the Company fails to complete its initial Business Combination within the Combination Period. The Company’s anchor investors have agreed to (1) vote any Founder Shares held by them in favor of the initial Business Combination, (2) waive their redemption rights with respect to any Founder Shares held by them in connection with the completion of the Company’s initial Business Combination, and (3) waive their rights to liquidating distributions from the Trust Account with respect to any Founder Shares held by them if the Company fails to complete its initial Business Combination within the Combination Period.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="color: rgb(35, 31, 32); font-family: 'Times New Roman'; font-size: 10pt;">On November 22, 2022, the Company held a special meeting of stockholders. At the meeting, the Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware extending, upon the request of the Sponsor and approval by the Board, the period of time for the Company to consummate an initial business combination up to four times, each by an additional three months, for an aggregate of 12 additional months (which is from September 8, 2022 up to September 8, 2023).</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="color: rgb(35, 31, 32); font-family: 'Times New Roman'; font-size: 10pt;">In connection with the special meeting of stockholders, stockholders holding 5,658 shares of the Company’s Class A common stock exercised their right to redeem such shares for a pro rata portion of the funds in the Company’s trust account. As a result, $58,916 (approximately $10.41 per share) was removed from the Company’s trust account to pay such holders.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="color: rgb(35, 31, 32); font-family: 'Times New Roman'; font-size: 10pt;">On September 8, 2022, the Company issued a promissory note in the aggregate principal amount of $2,875,000 to the Sponsor, in connection with the extension of the termination date for the Company’s initial Business Combination from September 8, 2022 to December 8, 2022. On December 19, 2022, the Company announced the second extension of the termination date for the Company’s initial Business Combination from December 8, 2022 to March 8, 2023. On February 28, 2023, the Company announced the third extension of the termination date for the Company’s initial Business Combination from March 8, 2023 to June 8, 2023.</div> <div style="color: rgb(35, 31, 32); font-family: 'Times New Roman'; font-size: 10pt;"> <br/> </div> <div style="color: rgb(35, 31, 32); font-family: 'Times New Roman'; font-size: 10pt;">On August 9, 2023, the Company and TMTG entered into the Second Amendment to the Merger Agreement (the “Second Amendment”). Among other changes to governance and financial terms, the Second Amendment extends the Merger Agreement’s “Outside Date” to December 31, 2023, and provides for mutual supplemental due diligence ahead of the Company’s anticipated filing of an updated registration statement on Form S-4 with the SEC. For further information on the Second Amendment, please see the Company’s current report on Form 8-K filed with the SEC on August 9, 2023 or the Company’s Amendment Number 1 to the Form S-4 Registration Statement filed with the SEC on November 13, 2023.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"> </div> <div style="color: rgb(35, 31, 32); font-family: 'Times New Roman'; font-size: 10pt;">On September 5, 2023, the Company held a special meeting of stockholders (the “Meeting”). At the Meeting, the Company’s stockholders approved the Extension Amendment extending, upon the approval by the Corporation’s board of directors, the date by which the Company has to consummate an initial business combination up to four times, each by an additional three months, for an aggregate of 12 additional months (i.e. from September 8, 2023 up to September 8, 2024) or such earlier date as determined by the Board (the “Extension Amendment Proposal”).</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="color: rgb(35, 31, 32); font-family: 'Times New Roman'; font-size: 10pt;">In connection with the Meeting, stockholders holding 28,745 shares of the Company’s Class A common stock exercised their right to redeem such shares for a pro rata portion of the funds in the Company’s Trust Account. As a result, $307,028 (approximately $10.68 per share) was removed from the Company’s Trust Account to pay such holders.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="color: rgb(35, 31, 32); font-family: 'Times New Roman'; font-size: 10pt;">On September 29, 2023, the Company and TMTG entered into the Third Amendment to the Merger Agreement (the “Third Amendment”). The Third Amendment extends the period of time for the parties to complete mutual supplemental due diligence ahead of the Company’s anticipated filing of an updated registration statement on Form S-4 with the SEC.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="color: rgb(35, 31, 32); font-family: 'Times New Roman'; font-size: 10pt;">The Company has until September 8, 2024, to consummate a Business Combination (the “Combination Period”). If the Company is unable to complete a Business Combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but no more than <span style="-sec-ix-hidden:Fact_b25797f16dec47d88f109a2e2a5a8422">five</span> business days thereafter, redeem 100% of the outstanding Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned (net of taxes payable and less interest to pay dissolution expenses up to $100,000), divided by the number of then outstanding Public Shares, which redemption will completely extinguish public stockholders’ rights as stockholders (including the right to receive further liquidation distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the remaining stockholders and the Company’s board of directors, proceed to commence a voluntary liquidation and thereby a formal dissolution of the Company, subject in each case to its obligations to provide for claims of creditors and the requirements of applicable law. The underwriter has agreed to waive its rights to the deferred underwriting commission held in the Trust Account in the event the Company does not complete a Business Combination within the Combination Period and, in such event, such amounts will be included with the funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution will be less than $10.45.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="color: rgb(35, 31, 32); font-family: 'Times New Roman'; font-size: 10pt;">The Sponsor has agreed that it will be liable to the Company, if and to the extent any claims by a vendor for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amounts in the Trust Account to below $10.20 per share (whether or not the underwriters’ over-allotment option is exercised in full), except as to any claims by a third party who executed a waiver of any and all rights to seek access to the Trust Account and except as to any claims under the Company’s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act. In the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (except for the company’s independent registered accounting firm), prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account.</div> <div style="color: rgb(35, 31, 32); font-family: 'Times New Roman'; font-size: 10pt;"> <br/> </div> <div style="color: rgb(35, 31, 32); font-family: 'Times New Roman'; font-size: 10pt;">Going Concern Consideration</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="color: rgb(35, 31, 32); font-family: 'Times New Roman'; font-size: 10pt;">In connection with the Company’s assessment of going concern considerations in accordance with Financial Accounting Standard Board’s Account Standards Update (“ASU”) 2014-15, “Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” as stated above, the Company has until September 8, 2024 to consummate a Business Combination. It is uncertain that the Company will be able to consummate a Business Combination by this time. If a Business Combination is not consummated by this date, there will be a mandatory liquidation and subsequent dissolution of the Company. Additionally, the Company has incurred and expects to incur significant costs in pursuit of its acquisition plans. The Company lacks the financial resources it needs to sustain operations for a reasonable period of time, which is considered to be one year from the date of the issuance of the financial statements. As a result, these factors raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from</div> <div style="color: rgb(35, 31, 32); font-family: 'Times New Roman'; font-size: 10pt;">the outcome of these uncertainties.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="color: rgb(35, 31, 32); font-family: 'Times New Roman'; font-size: 10pt;">Proposed Business Combination</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="color: rgb(35, 31, 32); font-family: 'Times New Roman'; font-size: 10pt;">The Company entered into an Agreement and Plan of Merger, dated as of October 20, 2021, as amended on May 11, 2022, on August 9, 2023, and on September 29, 2023, and as it may be further amended or supplemented from time to time, the “Merger Agreement”) with DWAC Merger Sub Inc., a Delaware corporation and a wholly-owned subsidiary of the Company (“Merger Sub”), Trump Media &amp; Technology Group Corp., a Delaware corporation (“TMTG”), the Sponsor, in the capacity as the representative for certain stockholders of the Company, and TMTG’s General Counsel, in the capacity as the representative for stockholders of TMTG.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"> </div> <div style="color: rgb(35, 31, 32); font-family: 'Times New Roman'; font-size: 10pt;">Pursuant to the Merger Agreement, subject to the terms and conditions set forth therein, (i) upon the consummation of the transactions contemplated by the Merger Agreement (the “Closing”), Merger Sub will merge with and into TMTG (the “Merger” and, together with the other transactions contemplated by the Merger Agreement, the “Transactions”), with TMTG continuing as the surviving corporation in the Merger and a wholly- owned subsidiary of the Company. In the Merger, (i) all shares of TMTG common stock (together, “TMTG Common Stock”) issued and outstanding immediately prior to the effective time of the Merger (the “Effective Time”) (other than those properly exercising any applicable dissenters rights under Delaware law) will be converted into the right to receive the Merger Consideration (as defined below); (ii) each outstanding option to acquire shares of TMTG Common Stock (whether vested or unvested) will be assumed by the Company and automatically converted into an option to acquire shares of the Company common stock, with its price and number of shares equitably adjusted based on the conversion ratio of the shares of TMTG Common Stock into the Merger Consideration and (iii) each outstanding restricted stock unit of TMTG shall be converted into a restricted stock unit relating to shares of the Company’s common stock. At the Closing, the Company will change its name to “Trump Media &amp; Technology Group Corp.”</div> <div style="color: rgb(35, 31, 32); font-family: 'Times New Roman'; font-size: 10pt;"> <br/> </div> <div style="color: rgb(35, 31, 32); font-family: 'Times New Roman'; font-size: 10pt;">The aggregate merger consideration to be paid pursuant to the Merger Agreement to holders of TMTG Common Stock as of immediately prior to the Effective Time (“TMTG Stockholders” and, together with the holders of TMTG options and restricted stock units immediately prior to the Effective Time, the “TMTG Security Holders”) will be an amount equal to $875,000,000, subject to adjustments for TMTG’s closing debt, net of cash and unpaid transaction expenses (the “Merger Consideration”), plus the additional contingent right to receive certain earnout shares after the Closing, provided that it shall exclude any additional shares issuable upon conversion of certain TMTG convertible notes. The Merger Consideration to be paid to TMTG Stockholders will be paid solely by the delivery of new shares of the Company’s common stock, with each valued at the price per share at which each share of the Company’s common stock is redeemed or converted pursuant to the redemption by the Company of its public stockholders in connection with the Company’s initial Business Combination, as required by the Company’s Amended and Restated Certificate of Incorporation, by-laws and the Company’s Initial Public Offering prospectus. The Merger Consideration will be subject to a post-Closing true up 90 days after the Closing.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"> </div> <div style="color: rgb(35, 31, 32); font-family: 'Times New Roman'; font-size: 10pt;">As part of the Merger Consideration, the Company will create a new class of common stock (the “High Vote Common Stock”) to be issued to former President Donald J. Trump (“Company Principal”) that will have the same voting, dividend, liquidation and other rights as one share of the Company’s Class A common stock, except that each share of High Vote Common Stock will entitle its holder to a number of votes equal to the greater of (i) one vote and (ii) the number of votes that would cause the aggregate number of shares issued to the Company Principal as consideration in the Merger (excluding any Earnout Shares) to represent 55% of the voting power (to the maximum extent permitted by the rules and regulations of Nasdaq and applicable law, following the reasonable best efforts of the Company to obtain any necessary approvals) of (A) all shares of the Company’s common stock entitled to vote on the election of directors as of immediately following the Closing plus (B) the maximum number of shares of the Company’s common stock issuable upon the conversion of all convertible preferred stock or other convertible securities of the Company (if any) outstanding or with respect to which purchase agreements are in effect at Closing. The shares of High Vote Common Stock will vote together with all other shares of the Company’s common stock on all matters put to a vote of the Company’s stockholders, entitled to vote on the election of directors as of immediately following closing of the merger and all other matters put to a vote of the Company’s stockholders. Each TMTG convertible note that is issued and outstanding immediately prior to the Effective Time will convert immediately prior to the Effective Time into a number of shares of TMTG Common Stock in accordance with the terms of each note.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"> </div> <div style="color: rgb(35, 31, 32); font-family: 'Times New Roman'; font-size: 10pt;">In addition to the Merger Consideration set forth above, the TMTG Stockholders will also have a contingent right to receive up to an additional 40,000,000 shares of the Company’s common stock (the “Earnout Shares”) after the Closing based on the price performance of the Company’s common stock during the three (3) year period following the Closing (the “Earnout Period”). The Earnout Shares shall be earned and payable during the Earnout Period as follows:</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"> </div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 18pt;"><br/> </td> <td style="width: 15pt; vertical-align: top; color: rgb(35, 31, 32);"><span style="font-family: Times New Roman">●</span></td> <td style="width: auto; vertical-align: top;"> <div style="color: rgb(35, 31, 32);">if the dollar volume-weighted average price (“VWAP”) of the Company’s common stock equals or exceeds $12.50 per share for any 20 trading days within any 30 trading day period, the Company shall issue to the TMTG Stockholders an aggregate of 15,000,000 Earnout Shares;</div> </td> </tr> </table> <div style="font-family: 'Times New Roman'; font-size: 10pt;"> </div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 18pt;"><br/> </td> <td style="width: 15pt; vertical-align: top; color: rgb(35, 31, 32);"><span style="font-family: Times New Roman">●</span></td> <td style="width: auto; vertical-align: top;"> <div style="color: rgb(35, 31, 32);">if the VWAP of the Company’s common stock equals or exceeds $15.00 per share for any 20 trading days within any 30 trading day period, the Company shall issue to the TMTG Stockholders an aggregate of 15,000,000 Earnout Shares; and</div> </td> </tr> </table> <div style="font-family: 'Times New Roman'; font-size: 10pt;"> </div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 18pt;"><br/> </td> <td style="width: 15pt; vertical-align: top; color: rgb(35, 31, 32);"><span style="font-family: Times New Roman">●</span></td> <td style="width: auto; vertical-align: top;"> <div style="color: rgb(35, 31, 32);">if the VWAP of the Company’s common stock equals or exceeds $17.50 per share for any 20 trading days within any 30 trading day period, the Company shall issue to the TMTG Stockholders an aggregate of 10,000,000 Earnout Shares.</div> </td> </tr> </table> <div style="font-family: 'Times New Roman'; font-size: 10pt;"> </div> <div style="color: rgb(35, 31, 32); font-family: 'Times New Roman'; font-size: 10pt;">If there is a final determination that the TMTG Stockholders are entitled to receive Earnout Shares, then such Earnout Shares will be allocated pro rata amongst the TMTG Stockholders. The number of shares of the Company’s common stock constituting any earnout payment shall be equitably adjusted for stock splits, stock dividends, combinations, recapitalizations and the like after the Closing.</div> <div><br/></div> <div style="color: rgb(35, 31, 32); font-family: 'Times New Roman'; font-size: 10pt;">On December 4, 2021, in support of the Transactions, the Company entered into securities purchase agreements (the “SPAs”) with certain institutional accredited investors (the “PIPE Investors”), pursuant to which the investors agreed to purchase an aggregate of 1,000,000 shares of the Company’s Series A Convertible Preferred Stock (the “Preferred Stock”), at a purchase price of $1,000 per share of Preferred Stock, for an aggregate commitment of $1,000,000,000 in a private placement (the “PIPE”) that was originally intended to be consummated concurrently with the Transactions. The closing of the PIPE was conditioned on the concurrent closing of the Transactions and other closing conditions as set forth in the SPAs. Pursuant to the SPAs, each of the PIPE Investors had the right to terminate its respective SPA, among other things, if the closing of the PIPE had not occurred on or prior to September 20, 2022. The PIPE Investment was terminated in full as of January 10, 2024. See Note 9 – Subsequent Events.</div>
CY2023 djt Percentage Obligation To Redeem Public Shares If Entity Does Not Complete Business Combination
PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination
1
CY2021Q4 djt Number Of Earnout Period
NumberOfEarnoutPeriod
P3Y
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<div style="color: rgb(35, 31, 32); font-family: 'Times New Roman'; font-size: 10pt;">Use of Estimates</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"> </div> <div style="color: rgb(35, 31, 32); font-family: 'Times New Roman'; font-size: 10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.</div> <div style="color: rgb(35, 31, 32); font-family: 'Times New Roman'; font-size: 10pt;"> <br/> </div> <span style="color: rgb(35, 31, 32); font-family: 'Times New Roman'; font-size: 10pt;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates</span>
CY2022Q3 djt Percentage Of Excise Tax
PercentageOfExciseTax
0.01
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="color: rgb(35, 31, 32); font-family: 'Times New Roman'; font-size: 10pt;">Concentration of Credit Risk</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="color: rgb(35, 31, 32); font-family: 'Times New Roman'; font-size: 10pt;">Financial instruments that potentially subject the Company to concentration of credit risk consist of a cash account in a financial institution which, at times may exceed the Federal depository insurance coverage of $250,000. At December 31, 2023, the Company had not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.</div>
CY2023Q4 djt Percentage Of Deferred Underwriting Commission Based On Gross Proceeds From Ipo
PercentageOfDeferredUnderwritingCommissionBasedOnGrossProceedsFromIpo
-0.035
CY2023Q4 djt Deferred Underwriting Compensation
DeferredUnderwritingCompensation
10062500
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Legal Settlements
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements
4562100
CY2022 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
-3078967
CY2023Q4 djt Loss Contingency Period Of Plaintiff Allegation
LossContingencyPeriodOfPlaintiffAllegation
P6M

Files In Submission

Name View Source Status
0001140361-24-016719-index-headers.html Edgar Link pending
0001140361-24-016719-index.html Edgar Link pending
0001140361-24-016719.txt Edgar Link pending
0001140361-24-016719-xbrl.zip Edgar Link pending
djt-20240325.xsd Edgar Link pending
ef20025342_8k.htm Edgar Link pending
ef20025342_ex10-33.htm Edgar Link pending
ef20025342_ex10-36.htm Edgar Link pending
ef20025342_ex10-37.htm Edgar Link pending
ef20025342_ex10-7.htm Edgar Link pending
ef20025342_ex10-8.htm Edgar Link pending
ef20025342_ex14-1.htm Edgar Link pending
ef20025342_ex16-2.htm Edgar Link pending
ef20025342_ex21-1.htm Edgar Link pending
ef20025342_ex23-1.htm Edgar Link pending
ef20025342_ex3-2.htm Edgar Link pending
ef20025342_ex99-1.htm Edgar Link pending
ef20025342_ex99-2.htm Edgar Link pending
ef20025342_ex99-3.htm Edgar Link pending
ef20025342_ex99-4.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image001.jpg Edgar Link pending
image01.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
djt-20240325_def.xml Edgar Link unprocessable
djt-20240325_lab.xml Edgar Link unprocessable
djt-20240325_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
ef20025342_8k_htm.xml Edgar Link completed
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
djt-20240325_cal.xml Edgar Link unprocessable